Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Enterprise Value (2016 - 2025)

Ani Pharmaceuticals' Enterprise Value history spans 16 years, with the latest figure at -$285.6 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 97.12% year-over-year to -$285.6 million; the TTM value through Dec 2025 reached -$285.6 million, down 97.12%, while the annual FY2025 figure was -$285.6 million, 97.12% down from the prior year.
  • Enterprise Value for Q4 2025 was -$285.6 million at Ani Pharmaceuticals, down from -$262.6 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$15.3 million in Q3 2021 and bottomed at -$285.6 million in Q4 2025.
  • The 5-year median for Enterprise Value is -$145.0 million (2024), against an average of -$137.6 million.
  • The largest annual shift saw Enterprise Value crashed 718.38% in 2021 before it surged 49.45% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$105.3 million in 2021, then soared by 49.45% to -$53.2 million in 2022, then tumbled by 315.38% to -$221.1 million in 2023, then surged by 34.47% to -$144.9 million in 2024, then crashed by 97.12% to -$285.6 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Enterprise Value are -$285.6 million (Q4 2025), -$262.6 million (Q3 2025), and -$217.8 million (Q2 2025).